SCHEMBL18153356

SCHEMBL18153356

COc1cc(Cl)nc(N2CCN(C(=O)OC(C)(C)C)CC2)n1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SUV39H2 Q9H5I1 4/20 0.46
GPR119 Q8TDV5 4/20 0.45
SLC2A1 P11166 1/20 0.45
TLR9 Q9NR96 2/20 0.44
ACHE P22303 1/20 0.44
TLR7 Q9NYK1 1/20 0.44
POLB P06746 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
MAPT P10636 1/20 0.43
PIK3CA P42336 1/20 0.43
CKS1B P61024 1/20 0.43
SKP1 P63208 1/20 0.43
SKP2 Q13309 1/20 0.43
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43
ALK Q9UM73 1/20 0.43
PTPN11 Q06124 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24851896 0.91 GPR119 (0.50) GPR119ACHEPOLBMEN1KMT2A
SCHEMBL10412083 0.86 MEN1 (0.52) GPR119ACHEPOLBMEN1KMT2A
SCHEMBL30162245 0.86 CKS1B (0.49) SUV39H2GPR119ACHEPOLBMEN1
SCHEMBL24851452 0.86 CKS1B (0.49) SUV39H2GPR119ACHEPOLBMEN1
SCHEMBL24851165 0.86 MEN1 (0.53) SUV39H2GPR119ACHEPOLBMEN1
SCHEMBL30995286 0.85 SLC2A1 (0.46) GPR119SLC2A1TLR9ACHETLR7
SCHEMBL29931618 0.85 PIK3CA (0.48) GPR119ACHEPOLBMEN1KMT2A
SCHEMBL27029463 0.85 PIK3CA (0.48) GPR119ACHEPOLBMEN1KMT2A
SCHEMBL24851765 0.83 GBA1 (0.51) SUV39H2GPR119MEN1KMT2ACKS1B
SCHEMBL18153313 0.83 TLR9 (0.45) SUV39H2GPR119TLR9ACHEPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3283472-B1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS UNIV INDIANA RES & TECH CORP (US) 2021-04-14 EP disclosed
US-10273228-B2 Hepatitis B viral assembly effectors INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2019-04-30 US disclosed
US-20180099952-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-04-12 US disclosed
US-20180099952-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-04-12 US disclosed
EP-3283472-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS Indiana University Research&Technology Corporation (US) 2018-02-21 EP disclosed
WO-2016168619-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2016-10-20 WO disclosed
WO-2016168619-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2016-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180099952-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS HAVCR2, MAVS, HCCS SUV39H2 4391/4885GPR119 3630/4885SLC2A1 4867/4885
US-10273228-B2 Hepatitis B viral assembly effectors HAVCR2, MAVS, HCCS SUV39H2 4391/4885GPR119 3630/4885SLC2A1 4867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.